Drug candidate NUZ-001 has shown strong safety characteristics in its latest human 3D brain model study, Neurizon Therapeutics (ASX:NUZ) has confirmed this week.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
“This is a very positive result,” Dr Michael Thurn told HotCopper, declaring on the company’s news: “We have been able to show NUZ-001 may have the potential to be a treatment for Alzheimer’s disease and Parkinson’s disease.”
“As you know, they are diseases that are becoming more and more important in aging populations so these results really set us up to look at these two indications going forward.”
NUZ has been trading 4.7% lower on Monday and is now selling at 10cps.
Join the discussion. See what HotCopper users are saying about Neurizon Therapeutics and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.